1-ethoxycarbonyl-4-(2-methoxyphenyl)but-3-ene | 110949-94-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-ethoxycarbonyl-4-(2-methoxyphenyl)but-3-ene
• 英文别名: ethyl (4E)-5-(2-methoxyphenyl)-4-pentenoate；Ethyl 5-(2-methoxyphenyl)pent-4-enoate；ethyl (E)-5-(2-methoxyphenyl)pent-4-enoate
• CAS: 110949-94-5
• 化学式: C₁₄H₁₈O₃
• 分子量: 234.295
• InChiKey: HBGTYFKIILIOQS-WEVVVXLNSA-N

物化性质

• 沸点：
  331.0±30.0 °C(Predicted)
• 密度：
  1.046±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-ethoxycarbonyl-4-(2-methoxyphenyl)but-3-ene 在 bis(norbornadiene)rhodium(l)tetrafluoroborate 、 (R)-(+)-1,1'-bi-2-naphthol 、 双氧水 、 三甲基铝 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 为溶剂， 反应 13.5h， 生成 (5R)-N-benzyl-5-hydroxy-5-(2-methoxyphenyl)pentanamide
  参考文献：
  名称：

  铑催化的γ，δ-不饱和酰胺衍生物的不对称硼氢化反应：δ-硼化酰胺†

  摘要：

  γ，δ-不饱和酰胺（其中烯基部分带有芳基或杂芳基取代基）通过频哪醇硼烷进行区域选择性铑催化的δ-硼化，从而获得手性仲苄基硼酸酯。结果对比了γ，δ-不饱和酰胺的γ-硼化，其中双取代的烯烃部分仅带有烷基取代基。区域化学的逆转与π-面部选择性意义上的逆转相结合。

  DOI：

  10.1039/c8cc01563e
• 作为产物：
  描述：

  [3-(乙氧羰基)丙基]三苯基溴化膦 在 potassium carbonate 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 51.0h， 生成 1-ethoxycarbonyl-4-(2-methoxyphenyl)but-3-ene
  参考文献：
  名称：

  手性磷酸催化级联小环的环化

  摘要：

  已经开发了以手性磷酸为有效催化剂的原位生成的醌甲基化物和邻氨基苯甲醛的不对称Prins环化反应。这种非常规的方法可以轻松获得各种功能化的反式吡喃//呋喃-四氢喹啉衍生物，且产率高，非对映和对映选择性（产率高达99％，ee高达99％）。力学研究表明，三个相邻的三级立体中心是通过C–O，CC和C–N键的顺序形成而构建的。

  DOI：

  10.1021/acs.orglett.9b02714

文献信息

• [EN] SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF<br/>[FR] PIPERIDINES AMINOANILINIQUES SECONDAIRES UTILISEES COMME ANTAGONISTES DE LA MCH1 ET UTILISATIONS CORRESPONDANTES
  申请人：SYNAPTIC PHARMACEUTICAL CORPOR

  公开号：WO2004005257A1

  公开（公告）日：2004-01-15

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

  本发明涉及对黑素集中激素-1（MCH1）受体具有选择性的拮抗剂化合物。该发明提供了一种含有治疗有效量的本发明化合物和药用辅料的药物组合物。本发明还提供了一种通过结合治疗有效量的本发明化合物和药用辅料制成的药物组合物。本发明进一步提供了一种制作含有治疗有效量的本发明化合物和药用辅料的药物组合物的方法。本发明还提供了一种减少主体体质量的方法，包括向主体施用有效减少主体体质量的本发明化合物的量。本发明还提供了一种治疗患有抑郁和/或焦虑的主体方法，包括向主体施用有效治疗主体的抑郁和/或焦虑的本发明化合物的量。本发明还提供了一种治疗患有尿路障碍的主体方法。
• Secondary amino anilinic piperidines as mch1 antagonists and uses thereof
  申请人：Marzabadi R. Mohammad

  公开号：US20050245743A1

  公开（公告）日：2005-11-03

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

  本发明涉及一种选择性抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供一种由本发明化合物的治疗有效量和药学上可接受的载体组成的药物组合物。本发明还提供一种制备药物组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。本发明还提供一种减轻受试者体重的方法，包括向受试者投予本发明化合物的有效量以减轻受试者的体重。本发明还提供一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者投予本发明化合物的有效量以治疗受试者的抑郁症和/或焦虑症。本发明还提供一种治疗患有泌尿系统疾病的受试者的方法。
• Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof
  申请人：H. Lunbeck A/S

  公开号：US07473698B2

  公开（公告）日：2009-01-06

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

  该发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。该发明提供了一种制药组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。该发明提供了一种制药组合物的制备方法，包括将本发明化合物的治疗有效量和药学上可接受的载体结合。该发明还提供了一种减少受试者体重的方法，包括向受试者施用本发明化合物的有效量以减少受试者的体重。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者施用本发明化合物的有效量以治疗受试者的抑郁症和/或焦虑症。该发明还提供了一种治疗患有尿液障碍的受试者的方法。
• Ihara, Masataka; Toyota, Masahiro; Abe, Mariko, Journal of the Chemical Society. Perkin transactions I, 1986, p. 1543 - 1550
  作者：Ihara, Masataka、Toyota, Masahiro、Abe, Mariko、Ishida, Yohhei、Fukumoto, Keiichiro、Kametani, Tetsuji

  DOI：——

  日期：——
• US7473698B2
  申请人：——

  公开号：US7473698B2

  公开（公告）日：2009-01-06